Analytical Data
-
Gene name
CD42b/GP1BA
- Application
-
Alternative Names
GP1Ba; CD42-B; CD42b-Alpha; GP1-BA; BSS; GP1B; GPIBA; Glycocalicin; Glycoprotein Ib Alpha Polypeptide, Platelet
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O35930
-
Expression Region
Gln17~Thr282
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD42b, also known as glycoprotein Ib alpha (GP1BA), is a critical component of the platelet membrane receptor complex involved in hemostasis and thrombosis. Functioning as a primary receptor for von Willebrand factor (vWF), CD42b/GP1BA plays an essential role in platelet adhesion to sites of vascular injury, which is crucial for the formation of a stable blood clot. Abnormalities in this receptor can lead to bleeding disorders, such as Bernard-Soulier syndrome, characterized by impaired platelet function due to defective GP1BA expression. The recombinant protein of CD42b/GP1BA has garnered significant interest for its potential applications in both research and clinical settings. Studying this protein enhances our understanding of platelet biology and the molecular mechanisms underlying thrombosis and hemostasis. Furthermore, the recombinant form allows for the investigation of therapeutic strategies aimed at modulating platelet function in various hematological conditions. By creating a reliable source of CD42b/GP1BA, researchers can generate specific antibodies, screen for inhibitors, and develop diagnostic tools that can aid in the management of clotting disorders. Overall, the research surrounding CD42b/GP1BA recombinant protein addresses fundamental questions in vascular biology, while also offering promising avenues for therapeutic intervention in thrombotic and hemorrhagic diseases.
